ASCO 2021: First Results of PEACE-1: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone And/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (
Cancer Trial Results
PEACE-1: OS in mCSPC - Slideset Download - ESMO 2021 | CCO
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
New Standard for Metastatic Castration-Sensitive Prostate Cancer? | MedPage Today
2021 ESMO Updates on Practice-Changing Trials in Prostate Cancer: STAMPEDE and PEACE-1 | VuMedi
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
ASCO 2021: First Results of PEACE-1: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone And/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
ESMO Open on Twitter: "#ESMO21 presidential symposium: overall survival with abiraterone acetate plus prednisone in #PEACE-1 - check out Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic #prostatecancer
OncoTimes Updates (@OncoTimes) / Twitter
PEACE-1 and STAMPEDE Trials Abiraterone Acetate Plus Prednisolone in Prostate Cancer - The ASCO Post
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
Neeraj Agarwal, MD, FASCO on Twitter: "#ESMO21 Peace-1 trial results 👉Treatment of high volume denovo metastatic castration sensitive prostate cancer changes again👉triplet therapy with ADT+docetaxel+abiraterone is new standard of care option for
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial - The Lancet Oncology
Cancer Trial Results
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
Cancer Trial Results
ASCO 2021: First Results of PEACE-1: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone And/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (
Therapie des metastasierten hormonsensitiven Prostatakarzinoms
Survival with Abiraterone Acetate Plus Prednisone in PEACE-1 | GU Oncology Now
OVERVIEW TARGET AUDIENCE LEARNING OBJECTIVES FACULTY
EAU 2021: Detailed Analysis of Radiographic Progression-Free Survival in the PEACE-1 Phase 3 Trial
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
Adding abiraterone acetate to standard of care prolongs survival in prostate cancer subset
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis - ScienceDirect
